data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
SELLAS Life Sciences Gr
(NASDAQ:SLS)
$2.32
0.12[5.45%]
Last update: 2:23PM
Day High/Low2.17 - 2.4
52 Week High/Low2.1 - 10.82
Open / Close2.28 / -
Float / Outstanding20.5M / 20.5M
Vol / Avg.94.5K / 301.1K
Mkt Cap47.6M
P/E-
50d Avg. Price2.72
Div / Yield-
Payout Ratio-
EPS-1.05
Total Float20.5M

SELLAS Life Sciences Gr (NASDAQ:SLS), Quotes and News Summary

SELLAS Life Sciences Gr (NASDAQ: SLS)

Day High/Low2.17 - 2.4
52 Week High/Low2.1 - 10.82
Open / Close2.28 / -
Float / Outstanding20.5M / 20.5M
Vol / Avg.94.5K / 301.1K
Mkt Cap47.6M
P/E-
50d Avg. Price2.72
Div / Yield-
Payout Ratio-
EPS-1.05
Total Float20.5M
Benzinga - Jun 28, 2022, 8:41AM
Benzinga - Jun 27, 2022, 8:31AM
Benzinga - Jun 8, 2022, 12:03PM
Benzinga - Jun 8, 2022, 8:15AM
Benzinga - May 26, 2022, 10:10AM
Benzinga - May 26, 2022, 8:32AM
Benzinga - May 12, 2022, 4:42PM
Benzinga - Apr 26, 2022, 9:12AM
Benzinga - Apr 11, 2022, 8:19AM
Benzinga - Apr 6, 2022, 7:11AM
Benzinga - Apr 1, 2022, 8:41AM
Benzinga - Apr 1, 2022, 8:19AM
Benzinga - Mar 31, 2022, 5:11PM
Benzinga - Mar 31, 2022, 4:12PM
Benzinga - Mar 31, 2022, 4:11PM
Benzinga - Feb 1, 2022, 8:32AM
Sector: Health Care.Industry: Biotechnology
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. Its product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The company is also developing GFH009, a small molecule, CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai) Inc, for all therapeutic and diagnostic uses in the world outside of Greater China.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-11
REV
Q1 2022Est.ActualSurprise
EPS-1.050
REV1.000M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

SELLAS Life Sciences Gr Questions & Answers

Q
How do I buy SELLAS Life Sciences Gr (SLS) stock?
A

You can purchase shares of SELLAS Life Sciences Gr (NASDAQ: SLS) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are SELLAS Life Sciences Gr's (SLS) competitors?
Q
What is the target price for SELLAS Life Sciences Gr (SLS) stock?
A

The latest price target for SELLAS Life Sciences Gr (NASDAQ: SLS) was reported by Cantor Fitzgerald on Tuesday, June 28, 2022. The analyst firm set a price target for 6.00 expecting SLS to rise to within 12 months (a possible 158.62% upside). 2 analyst firms have reported ratings in the last year.

Q
Current Stock Price for SELLAS Life Sciences Gr (SLS)?
A

The stock price for SELLAS Life Sciences Gr (NASDAQ: SLS) is $2.32 last updated Today at July 5, 2022, 6:23 PM UTC.

Q
Does SELLAS Life Sciences Gr (SLS) pay a dividend?
A

There are no upcoming dividends for SELLAS Life Sciences Gr.

Q
When is SELLAS Life Sciences Gr (NASDAQ:SLS) reporting earnings?
A

SELLAS Life Sciences Gr’s Q2 earnings are confirmed for Thursday, August 11, 2022.

Q
Is SELLAS Life Sciences Gr (SLS) going to split?
A

There is no upcoming split for SELLAS Life Sciences Gr.

Q
What sector and industry does SELLAS Life Sciences Gr (SLS) operate in?
A

SELLAS Life Sciences Gr is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.